267 related articles for article (PubMed ID: 27460552)
1. Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis.
Spyropoulos E; Kotsiris D; Spyropoulos K; Panagopoulos A; Galanakis I; Mavrikos S
Clin Genitourin Cancer; 2017 Feb; 15(1):129-138.e1. PubMed ID: 27460552
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
3. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
5. The establishment and evaluation of a new model for the prediction of prostate cancer.
Wang Q; Li YF; Jiang J; Zhang Y; Liu XD; Li K
Medicine (Baltimore); 2017 Mar; 96(11):e6138. PubMed ID: 28296726
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
7. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011.
Na R; Jiang H; Kim ST; Wu Y; Tong S; Zhang L; Xu J; Sun Y; Ding Q
PLoS One; 2012; 7(11):e49914. PubMed ID: 23189170
[TBL] [Abstract][Full Text] [Related]
9. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
[TBL] [Abstract][Full Text] [Related]
10. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
11. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
12. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
13. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
14.
Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of a scoring system for predicting the positive rate of prostatic biopsy for prostate cancer].
Chen JG; Chen XF; Gu DH; Lu M; Zheng B; Zhang B; Pan B; Zhu H; Pan XD; Xu B; Qian L
Zhonghua Nan Ke Xue; 2015 Jan; 21(1):53-6. PubMed ID: 25707141
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
18. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M
Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.
Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH
J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138
[TBL] [Abstract][Full Text] [Related]
20. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
